These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 18406645)

  • 1. Natalizumab treatment in pediatric multiple sclerosis: a case report.
    Borriello G; Prosperini L; Luchetti A; Pozzilli C
    Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab use in pediatric multiple sclerosis.
    Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
    Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
    Berger JR
    Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
    Putzki N; Yaldizli O; Bühler R; Schwegler G; Curtius D; Tettenborn B
    Eur Neurol; 2010; 63(2):101-6. PubMed ID: 20090344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
    Horga A; Castillo J; Rio J; Tintore M; Auger C; Sastre-Garriga J; Edo MC; Perez-Miralles F; Tur C; Nos C; Huerga E; Comabella M; Rovira A; Montalban X
    Rev Neurol; 2011 Mar; 52(6):321-30. PubMed ID: 21387248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.
    Waubant E; Chabas D; Okuda DT; Glenn O; Mowry E; Henry RG; Strober JB; Soares B; Wintermark M; Pelletier D
    Arch Neurol; 2009 Aug; 66(8):967-71. PubMed ID: 19667217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
    Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.